Point of Care Diagnostics Market

The global point-of-care diagnostics market is expected to reach USD 77.8 billion by 2028 from an estimated USD 49.7 billion in 2023, at a CAGR of 9.4% from 2023 to 2028.

Globally, the number of diabetics is expected to grow from 643 million in 2030 to 783 million by 2045. Diabetes resulted in 6 million deaths worldwide in 2021, while 541 million people are estimated to be at risk of developing diabetes (Source: International Diabetes Federation).

To know about the assumptions considered for the study download the pdf brochure

Diseases/disorders such as diabetes, hematology disorders, cancer, and cardiac disorders are considered target conditions for POC testing as they require continuous monitoring. As a result, the increasing incidence and prevalence of these conditions are likely to drive the for the adoption of POC testing devices. Initiatives such as funding, training by Governments across  developed and developing nations to support the development and adoption of POC in their healthcare settings and the rising number of CLIA waivers point of care tests are expected to promote the market growth.

Key Players:

• F. Hoffman-La Roche Ltd. (Switzerland),
• Abbott Laboratories (US),
• BD (US),
• Danaher Corporation (US),
• Siemens Healthineers (Germany), and many more....

The point of care diagnostics business is competitive, with both established companies and newcomers competing for the same market share.

F. Hoffman-La Roche Ltd. (Switzerland):

In 2022, Roche Diagnostics became another leading player in the global POC diagnostics market. To expand its geographical footprint, the company emphasizes both organic and inorganic growth strategies. A strong focus on the expansion of R&D activities in new rapid test development. In August 2022, the company Roche launched its Elecsys IGRA SARS-CoV-2 test to assist in detecting individuals with a T-cell response to SARS-CoV-2, suggesting prior exposure to the virus or COVID-19 vaccination It focuses on implementing data management in existing pharmaceutical and diagnostic businesses.

Abbott Laboratories (US):

In 2022, Abbott Laboratories will be another leading player  in the point-of-care diagnostics market. Its strong focus on strengthening its brand presence, continuous investments in R&D, broad customer base, and geographical foothold are key factors contributing to its leading position in this market. To expand its global diagnostics presence and leadership in the point-of-care diagnostics market, the company acquired Alere, Inc. in October 2017. Abbott Laboratories is also engaged in R&D aims to create innovative products addressing the unmet needs of patients and healthcare providers. In May 2022, the  company received FDA clearance for its Alinity m STI Assay. The test simultaneously detects & differentiates four common sexually transmitted infections (STIs).

Global manufacturers in the Point of Care Diagnostics Market

• Becton, Dickinson and Company (BD) (United States),
• BioMérieux (France),
• Quidel Corporation (United States)
• Trinity Biotech plc (Ireland)
• Sysmex Corporation (Japan)
• Sekisui Diagnostics (United States), and many more....

These manufacurers plays a vital role in shaping the global future of the industry.

Becton, Dickinson and Company (BD) (United States):

BD is a global medical technology company that develops point-of-care diagnostic solutions for infectious diseases, oncology, and women's health. Their portfolio includes rapid antigen tests, molecular diagnostic assays, and blood culture systems designed to deliver actionable diagnostic insights at the point of care.

BioMérieux (France):

BioMérieux specializes in providing rapid diagnostic solutions for infectious diseases, sepsis management, and antimicrobial stewardship. Their point-of-care testing platforms include immunoassay analyzers, molecular diagnostic systems, and automated blood culture instruments for timely diagnosis and treatment optimization in clinical settings.

Quidel Corporation (United States):

Quidel Corporation develops and manufactures point-of-care diagnostic tests for respiratory infections, influenza, and gastrointestinal diseases. Their portfolio includes rapid antigen tests, molecular diagnostic assays, and immunoassay platforms designed for decentralized testing in physician offices, urgent care centers, and retail clinics.

Trinity Biotech plc (Ireland):

Trinity Biotech plc specializes in point-of-care diagnostic solutions for infectious diseases, diabetes, and autoimmune disorders. Their product portfolio includes rapid tests, immunoassay analyzers, and blood glucose monitoring systems designed for use in clinical laboratories, hospitals, and community healthcare settings.

Sysmex Corporation (Japan):

Sysmex Corporation offers point-of-care hematology and urinalysis solutions for clinical laboratories, physician offices, and emergency departments. Their handheld analyzers, automated systems, and digital microscopy platforms provide rapid and accurate assessment of blood and urine parameters for diagnostic decision-making.

Sekisui Diagnostics (United States):

Sekisui Diagnostics develops and manufactures rapid diagnostic tests and point-of-care analyzers for infectious diseases, cardiac markers, and women's health. Their portfolio includes lateral flow assays, immunoassay analyzers, and coagulation testing systems designed for use in diverse clinical settings worldwide.

Related Reports:

Point of Care Diagnostics Market by Product (Glucose, HIV, Hep C, HPV, Hematology, Pregnancy), Platform (Microfluidic, Dipstick, RT-PCR, INAAT), Sample(Blood, Urine), Purchase (OTC, Rx), End User (Pharmacy, Hospitals, Home Care) - Global Forecast to 2028

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]